Skip to main content
Published on May 12, 2026 | New 5th Edition

INTREPID Alliance updated review of antiviral compounds in clinical and preclinical development for fourteen priority viruses of pandemic potential

Introduction.
The Antiviral Development Landscape – 5th Edition

based on data from December 2024 to January 2026

In support of the G7’s recommended 100 Days Mission and the International Pandemic Preparedness Secretariat (IPPS), which seeks the “development of at least two ‘Phase 2 ready’ therapeutic candidates against the identified viral pathogen families of greatest pandemic potential,”1 the INTREPID Alliance committed in July 2023 to conduct a global landscape assessment of antiviral compound R&D. The landscape analysis intends to aid in the identification of clinical (e.g., Phase 2/3 ready) and preclinical antivirals aligned with the 100 Days Mission and highlight gaps in the pipeline.

INTREPID released the first four editions of the landscape analysis in January 2024, April 2024, October 2024, and April 2025. These updates were based on non-confidential information and provided the initial summary of the clinical and preclinical phase antiviral compounds across 13 viral families of pandemic potential.2,3,4 Clinical compounds were classified as noted in the updated definitions below.4 Preclinical compounds were classified as previously described.4

With today’s release of the Antiviral Clinical and Preclinical Development Landscape – 5th Edition we begin our scheduled reports with emphases on the changes in compound classification since the previous edition. In view of the evolving state of global viral disease threats, INTREPID evaluates the list of viral families to include in our landscape on an ongoing basis. Informed by the World Health Organization list of priority diseases,5 the 5th Edition Antiviral Landscape evaluates 14 viral families of pandemic potential, adding Phenuiviridae to the analysis.

The 5th Edition is based on evaluation of non-confidential information as of January 2025. Going forward, these INTREPID landscape reports will be updated as resources allow.

View the Executive Summary ›

View the complete presentation ›

Interactive Antiviral Pipeline

INTREPID will publish the interactive components of the 5th Edition Antiviral Landscape in June 2026. Until then, explore the interactive antiviral clinical and preclinical pipelines from the 4th Edition Antiviral Landscape below.

Interactive Antiviral Clinical Development Pipeline

In the interactive pipeline below, all compounds are reported by phase of clinical development, viral disease indication, viral target, developer, and approval status. Novel unapproved compounds in clinical development are classified as either Promising, Watch & Wait, Investigational Antiviral-Indication Expansion, or Investigational Antiviral-Indication Expansion Preclinical Exploratory.

5th Edition updates coming in June 2026.

Use scroll bar below to explore the full interactive pipeline.

Icon Investigational Antiviral-Indication Expansion
Icon Approved Antiviral-Indication Expansion
Icon Promising
Icon Watch & Wait

Indication Legend

Chapare hemorrhagic fever
COVID-19
Crimean Congo hemorrhagic fever
Dengue
Ebola
Japanese encephalitis
Hendra virus
Human Adenovirus A-G
Influenza
Lassa fever
Polio
Rhinovirus
Adeno
Arena
Argentine hemorrhagic fever
Chikungunya
Corona
Flavi
Hantavirus / Hanta
huAdenovirus
Lujo hemorrhagic fever
Marburg virus
Measles
MERS-CoV
Mpox
Nairo
Nipah virus
Orthomyxo
Parainfluenza
Paramyxo
Peribunya
Picorna
Pox
SARS-CoV-1
Smallpox/Other Pox Viruses
Toga
West Nile virus
Yellow fever
Zika
Filo
Junin virus
Seasonal coronavirus

We welcome feedback to improve our listing, which can be provided through this portal. As with our previous listings, developers are invited to submit non-confidential information on their compound candidates. All reports are updated semi-annually and based on non-confidential information.

Interactive Antiviral Preclinical Development Pipeline

In the interactive pipeline below, all preclinical compounds are reported by phase of preclinical development (Hit, Early Lead, Late Lead and Potential Candidate), viral disease indication, viral mechanism/target, and sponsor/developer.

5th Edition updates coming in June 2026.

Use scroll bar below to explore the full interactive pipeline.

COVID-19 Preclinical Compound/Indications (n=74)
Non-COVID-19 Preclinical Compound/Indications (n=51)

Indication Legend

COVID-19
Dengue
Hendra virus
Influenza
Chikungunya
Measles
MERS-CoV
Nipah virus
SARS-CoV-1
West Nile virus
Zika
Lassa fever
Seasonal coronavirus
Mpox
Yellow fever
Parainfluenza
Junin virus

We welcome feedback to improve our listing, which can be provided through this portal. As with our previous listings, developers are invited to submit non-confidential information on their compound candidates. All reports are updated semi-annually and based on non-confidential information.

Summary of Our 2026 Deliverables

  • Release of the 5th Edition of the Antiviral Clinical and Preclinical Development Landscape – May 2026
  • Publication of the In Vitro Assays and Animal Efficacy Models for Orthoflaviviruses – May 2026
  • Release of 5th Edition updates to the interactive clinical and preclinical development pipeline – June 2026
  • Publication of deep dive report on AViDD centers – June 2026
  • Manuscript publication on the significant gaps in the antiviral landscape for vector-borne viral diseases
  • Manuscript publication on in vitro assays and animal efficacy models for orthoflaviviruses
  • Updates to the Antiviral Clinical and Preclinical Development Landscape will be updated as resources allow
  • Additional INTREPID Alliance reports on direct-acting antivirals for select virus families or viral diseases will be published intermittently

Engagement with INTREPID Alliance

The INTREPID Alliance engages reactively with academic and biotech entities to understand their ongoing activity; compounds and compound/indications identified through this mechanism will be added in future iterations of the antiviral landscape. All such discussion is based on non-confidential information.

Treatments are considered an integral part of any effective pandemic response, with antivirals potentially playing an important role in saving lives. INTREPID will also engage with policymakers and public health bodies to ensure that antivirals are integrated appropriately into global and local efforts to be better prepared against future pandemics.

1- International Pandemic Preparedness Secretariat (IPPS). 100 Days Mission: Implementation Report – 2023. (January 2024).
2- Compounds included small molecules, peptides, and RNA-based compounds with known direct antiviral mechanisms of action, in vitro/in vivo activity, first-in-human (FIH) single ascending dose vs. multiple ascending dose data completed and no major safety signals observed.
3- 13 priority viral families identified by the INTREPID Alliance Scientific Working Group using the NIH/NIAID priority viral family list; World Health Organization priority disease areas; and Airfinity database of antivirals.
4- These compounds have been selected based on objective, scientific criteria, using publicly available sources, and at arm’s length from commercial influence of our member companies. See Criteria. The classification of compounds is based upon currently available information, and exclusively upon an assessment against these criteria. The so-called “Promising” clinical compounds include small molecules, peptides, and RNA-based compounds with known direct antiviral mechanisms of action, in vitro/in vivo activity, first-in-human (FIH) single ascending dose vs. multiple ascending dose data completed and no major safety signals observed; “Promising” is not a promotional claim. Preclinical “Potential Candidate” compounds have not been assessed by regulatory authorities to be safe and efficacious for the treatment of disease in humans. Our content is designed to be factual, informative and non-commercial. It is not designed or intended to advertise or promote any pharmaceutical product or therapy or to advance the commercial interests of any company.
5- World Health Organization (WHO). Prioritizing diseases for research and development in emergency contexts. Accessed: 10 May 2026.

Previous Editions

Antiviral Clinical Development Landscape - 1st Edition
(January 24, 2024)

View Now

Antiviral Clinical Development Landscape and Promising Clinical Compounds - 2nd Edition
(April 29, 2024)

View Now

Antiviral Clinical and Preclinical Development Landscape – 3rd Edition
(October 9, 2024)

View Now

Antiviral Clinical and Preclinical Development Landscape – 4th Edition (April 20, 2025)

View Now

Disclaimer

The INTREPID Alliance is a not-for-profit consortium of innovative biopharmaceutical companies and affiliates committed to accelerating antiviral research, aiming to ensure that we have a stronger pipeline and are better prepared for future pandemics.

As part of our efforts, the INTREPID Alliance maintains and publishes a centralized list of promising investigational candidate compounds, with the purpose of knowledge-sharing and to support better pandemic preparedness. These compounds have been selected based on objective, scientific criteria, using publicly available sources, and at arm’s length from commercial influence of our member companies. See criteria listed in the report “Antiviral Clinical Development Landscape and Promising Clinical Compounds.” The designation of certain compounds as promising is based upon currently available information, and exclusively upon an assessment against these criteria. “Promising” is not a promotional claim. Candidate compounds have not been assessed by regulatory authorities to be safe and efficacious for the treatment of disease in humans. Our content is designed to be factual, informative, and non-commercial. It is not designed or intended to advertise or promote any pharmaceutical product or therapy or to advance the commercial interests of any company.